Medial EarlySign Overview
Medial EarlySign’s AI-driven machine learning solutions empower healthcare stakeholders to keep patients healthier for extended periods. The company’s advanced models derive actionable clinical insights from massive datasets, helping improve patient outcomes, optimize diagnostics, and enhance medication management. Medial EarlySign's purpose-built development environment ensures precision decision-making, supported by peer-reviewed studies published by leading healthcare organizations worldwide. EarlySign helps clients identify people at high risk for conditions such as non-small cell lung cancer (NSCLC), lower GI disorders and cancers, prediabetic progression to diabetes, downstream diabetic complications, risk for flu and its complications, chronic kidney disease (CKD), COVID-19, and more. The company was named a cool vendor in "Cool Vendors in AI for Healthcare, 2017" by the Gartner Research Group and was a winner of the CMS AI Health Outcomes Challenge.
Cumulative Funding Raised Over Time ($)
$20.0MJun 2013
$50.0MMar 2018
Latest News
growth-positive
/PRNewswire/ -- Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical predictive analytics, today announced a significant...
Medial EarlySign, a company specializing in AI-based clinical predictive analytics, has achieved a significant milestone with the publication of its 30th validated study in the British Medical Journal Open Gastroenterology. The study highlights the effectiveness of EarlySigns ColonFlag™ algorithm in detecting colorectal cancer and high-risk adenomas. Authored by Dr. Ruth M. Ayling and Dr. Finbarr Cotter, the study underscores the potential of ColonFlag to aid in early cancer detection. Medial EarlySign emphasizes rigorous independent validation of its research, ensuring high standards of quality and reliability. The companys predictive platform is available worldwide, transforming health data into actionable insights to improve patient outcomes. This development is seen as growth-positive for the company, reinforcing its role in advancing AI-driven healthcare solutions.
growth-positive
לרוש יש תרופה מבטיחה - AI ישראלית תאתר עבורה מטופלים
Swiss pharmaceutical company Roche has partnered with Israeli start-up Medial EarlySign to identify patients who could benefit from its lung cancer drug, Alecensa. The drug has shown significant success in clinical trials, reducing the risk of disease progression or death by 76% compared to standard chemotherapy. However, the drug is most effective in patients with a specific gene mutation found in only 4-5% of lung cancer patients. Medial EarlySigns AI algorithms will help identify these patients at an early stage of the disease.
Partners
growth-positive
EarlySign Announces Strategic Collaboration Agreement with Roche on AI Solution for Early Detection of Lung Cancer
Medial EarlySign has announced a new partnership with Roche to develop innovative solutions for the early detection of lung cancer. The goal of the collaboration is to deliver validated clinical machine learning models that can identify high-risk individuals and lead to earlier diagnosis and treatment. The partnership builds on an existing collaboration between Roches Diagnostics division and EarlySign, which focused on a personalized health solution for gastric cancer. The collaboration aims to transform healthcare delivery through digital solutions and smart algorithms, improving patient outcomes and making care more affordable and sustainable.
Partners
growth-positive
Medial EarlySign signs deal with Roche to develop AI-enabled cancer detection tool
Israeli startup Medial EarlySign has partnered with Roche Diagnostics International to commercialize an AI tool for early cancer detection, starting with gastric cancer. The tool will use EarlySigns software that incorporates lab results, EHR data, and other clinical care. The partnership aims to improve the management and utilization of data to bring new diagnostic methodologies to the market. Medial EarlySign has previously partnered with Datos Health to offer an integrated platform for identifying high-risk patients. Roche Diagnostics has also shown interest in the digital health space and has collaborated with investment firm aMoon to launch an early-stage investment program focused on diagnostic technologies and digital health.
Partners
growth-positive
Israeli AI-driven early detection solution arms UK health provider with weapon against colon cancer
Medial EarlySign, an Israeli MedTech company, has announced that Barts Health, one of the largest National Health Service providers in the UK, has implemented its AI-driven clinical data solution, ColonFlag. The platform uses machine learning to analyze clinical data and identify patients at high risk of developing colon cancer. Barts Health, which operates five hospitals in East London, plans to expand the use of EarlySigns technology to other high-burden diseases. EarlySigns Back2Care platform, launched in June, offers health organizations four service bundles focused on specific clinical domains, prioritization, and readmission using routine EHR data.
CustomersPartnersExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $50M |
| Last funding | $30M |
| Stage | Mature |
| Rounds | 2 |
| Investors | 5 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | earlysign.com |
| Careers | Careers page |
Locations
HaNagar St 6, Hod Hasharon, Israel
6105 South Main Street, Aurora, CO, USA
Photos & Videos
3 item(s)
Medial EarlySign Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportDigital Medical DiagnosticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Artificial IntelligenceMachine LearningTags (23)
clinical-trialsdata-analyticsrisk-managementearly-detectionpatent-pendingdoctorscancerdigital-healthcarediagnosticsdecision-makingclinical-datahospitalshealthcare-providersdeep-learningpersonalizationprecision-medicineclinicsbig-datamachine-learningartificial-intelligencedecision-supportemrdiabetesGeographic Markets
United StatesGlobalIsraelMedial EarlySign Financials
$50M
Total funding
Undisclosed
Capital raised
$30M
Last funding
Mature
Funding stage
2
Total rounds
5
Investors
Cumulative Funding Raised Over Time ($)
$20.0MJun 2013
$50.0MMar 2018
Private Equity Funding
B Round
Mar 2018
$30M
aMoon Fund, Viola Ventures, Nir Kalkstein, Horizons Ventures
A Round
Jun 2013
$20M
Horizons Ventures, Li Ka-shing
Medial EarlySign Lifecycle
Cumulative Funding Raised Over Time
$20.0MJun 2013
$50.0MMar 2018
All Events
B Round
Mar 2018
$30M
aMoon Fund, Viola Ventures, Nir Kalkstein, Horizons Ventures
A Round
Jun 2013
$20M
Horizons Ventures, Li Ka-shing
Medial EarlySign News
29 articles
growth-positive
/PRNewswire/ -- Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical predictive analytics, today announced a significant...
Medial EarlySign, a company specializing in AI-based clinical predictive analytics, has achieved a significant milestone with the publication of its 30th validated study in the British Medical Journal Open Gastroenterology. The study highlights the effectiveness of EarlySigns ColonFlag™ algorithm in detecting colorectal cancer and high-risk adenomas. Authored by Dr. Ruth M. Ayling and Dr. Finbarr Cotter, the study underscores the potential of ColonFlag to aid in early cancer detection. Medial EarlySign emphasizes rigorous independent validation of its research, ensuring high standards of quality and reliability. The companys predictive platform is available worldwide, transforming health data into actionable insights to improve patient outcomes. This development is seen as growth-positive for the company, reinforcing its role in advancing AI-driven healthcare solutions.
growth-positive
לרוש יש תרופה מבטיחה - AI ישראלית תאתר עבורה מטופלים
Swiss pharmaceutical company Roche has partnered with Israeli start-up Medial EarlySign to identify patients who could benefit from its lung cancer drug, Alecensa. The drug has shown significant success in clinical trials, reducing the risk of disease progression or death by 76% compared to standard chemotherapy. However, the drug is most effective in patients with a specific gene mutation found in only 4-5% of lung cancer patients. Medial EarlySigns AI algorithms will help identify these patients at an early stage of the disease.
Partners
growth-positive
EarlySign Announces Strategic Collaboration Agreement with Roche on AI Solution for Early Detection of Lung Cancer
Medial EarlySign has announced a new partnership with Roche to develop innovative solutions for the early detection of lung cancer. The goal of the collaboration is to deliver validated clinical machine learning models that can identify high-risk individuals and lead to earlier diagnosis and treatment. The partnership builds on an existing collaboration between Roches Diagnostics division and EarlySign, which focused on a personalized health solution for gastric cancer. The collaboration aims to transform healthcare delivery through digital solutions and smart algorithms, improving patient outcomes and making care more affordable and sustainable.
Partners
growth-positive
Medial EarlySign signs deal with Roche to develop AI-enabled cancer detection tool
Israeli startup Medial EarlySign has partnered with Roche Diagnostics International to commercialize an AI tool for early cancer detection, starting with gastric cancer. The tool will use EarlySigns software that incorporates lab results, EHR data, and other clinical care. The partnership aims to improve the management and utilization of data to bring new diagnostic methodologies to the market. Medial EarlySign has previously partnered with Datos Health to offer an integrated platform for identifying high-risk patients. Roche Diagnostics has also shown interest in the digital health space and has collaborated with investment firm aMoon to launch an early-stage investment program focused on diagnostic technologies and digital health.
Partners
growth-positive
Israeli AI-driven early detection solution arms UK health provider with weapon against colon cancer
Medial EarlySign, an Israeli MedTech company, has announced that Barts Health, one of the largest National Health Service providers in the UK, has implemented its AI-driven clinical data solution, ColonFlag. The platform uses machine learning to analyze clinical data and identify patients at high risk of developing colon cancer. Barts Health, which operates five hospitals in East London, plans to expand the use of EarlySigns technology to other high-burden diseases. EarlySigns Back2Care platform, launched in June, offers health organizations four service bundles focused on specific clinical domains, prioritization, and readmission using routine EHR data.
CustomersPartnersExpand
growth-positive
Medial EarlySign and Centric Consulting Join Forces to Increase Hospital Adoption of Clinical AI Solutions
Medial EarlySign has announced a partnership with Centric Consulting to enable US-based hospitals and healthcare organizations to utilize existing data for patient care. The partnership will combine Centrics consulting services with EarlySigns AI-powered solutions to prioritize patient procedures, deliver interventions, and re-engage populations. The focus will be on EarlySigns Infectious Disease bundle, given the ongoing COVID-19 pandemic. The partnership follows the recent launch of EarlySigns Back2Care suite of clinical data solutions, which offers solutions for high-burden diseases. The goal is to optimize resources and provide personalized and focused care. Medial EarlySign aims to expand its reach by engaging with Centrics network to support hospitals in improving patient outcomes.
Partners
growth-positive
Health AI Leader Medial EarlySign Launches New Suite of Clinical Data Solutions to Optimize Patient Care
Medial EarlySign has launched its new Back2Care platform, which offers AI-powered solutions to help healthcare organizations prioritize and expedite care for high-risk patients. The platform uses routine data to identify and prioritize patients who will benefit from accelerated attention, providing actionable insights into patient and population health. The launch of the Back2Care suite of bundled solutions aims to address the backlog of patients in need of screenings and ongoing care, as well as prepare healthcare organizations for potential surges of COVID-19 patients. Medial EarlySigns expansion of its digital solutions is intended to assist healthcare organizations in successfully transitioning back to care after the disruption caused by the coronavirus pandemic.
CustomersPartners
growth-positive
KLAS Research Recognizes Medial EarlySign as Emerging Healthcare AI Company
Medial EarlySign, a leader in AI-based clinical solutions, has been recognized as an emerging healthcare AI company in a new KLAS Research eTech Spotlight Report. The report highlights EarlySigns ability to help healthcare organizations predict and manage high-risk patients across various health conditions. EarlySign received an overall grade of A and was praised for its user-friendly product and service-oriented culture. Customers reported high satisfaction with the executive engagement and customer support. EarlySigns outcome-focused software solutions, AlgoMarkers, can help identify patients at high risk for various conditions. The companys rigorous algorithms are trained on large datasets and validated on millions of individuals. Medial EarlySign was founded in 2013 and is headquartered in Tel Aviv, Israel.
Customers
growth-positive
Medial EarlySign, Israeli HMO Maccabi Launch AI Algorithm To Detect High-Risk COVID-19 Cases
Maccabi Healthcare Services will deploy an AI-powered algorithm to identify individuals at high risk of severe COVID-19 complications. The algorithm, developed by Medial EarlySign and the Kahn-Sagol-Maccabi Research and Innovation Institute, analyzes electronic health records to assess people based on pre-existing conditions and other health factors. The algorithm has already identified 2% of Maccabi members as high-risk patients. When a high-risk individual reports COVID-19-like symptoms, the system automatically notifies medical professionals for immediate testing. The goal is to reduce severe COVID-19 cases and save lives. Maccabi Healthcare Services is in talks with US medical systems interested in implementing the algorithm.
Customers
growth-positive
Maccabi, Medial EarlySign develop algorithm to identify high-risk COVID-19 cases
Maccabi Healthcare Services, Israels largest HMO, has announced an AI algorithm developed by Medial EarlySign and the Kahn-Sagol-Maccabi Research and Innovation Institute. The algorithm analyzes electronic health records to identify individuals at high risk for severe COVID-19 complications. It will help Maccabi provide more effective treatment and fast-tracked testing procedures for high-risk patients. The algorithm considers variables such as age, medical history, weight, and tobacco use. Maccabi is in talks with US medical providers interested in using the algorithm for their COVID-19 response.
Customers
growth-positive
Israeli AI System Helps Save Lives By Flagging Patients At High Risk Of Flu Complications
Israeli company Medial EarlySign has been chosen by Maccabi Healthcare Services to enhance its flu vaccination campaign. Medial EarlySigns machine learning-based system will be used to identify patients at high risk of developing flu-related complications. The aim of the joint project is to reach out to high-risk individuals and gain insights to improve the model. Medial EarlySign has previously partnered with Maccabi to identify individuals at high risk of colorectal cancer. The flu season in Israel has been particularly harsh this year, with an increase in patients seeking treatment for flu-like symptoms and a higher rate of severe influenza cases requiring hospitalization.
CustomersPartners
growth-positive
Predictive Patient Care Startup Medial EarlySign Partners With Israeli HMO on Flu Vaccine Campaign
Medial EarlySign has partnered with Maccabi Healthcare Services to enhance their flu vaccination campaign by integrating EarlySigns flu algorithm to target high-risk individuals. Financial details were not disclosed.
Partners
growth-positive
Geisinger and Medial EarlySign Advance to First Stage of CMS AI Health Outcomes Challenge
Geisinger and EarlySign have been recognized for their joint proposal in the AI Health Outcomes Challenge. The proposal aims to apply advanced AI and machine learning algorithms to predict unplanned hospital readmissions and adverse events. Geisingers Chief Data Informatics Officer, David Vawdrey, highlights the financial and clinical burdens caused by preventable adverse patient events, and the partnership with EarlySign aims to improve patient outcomes and decrease healthcare costs. The CMS will announce Stage 2 finalists in April 2020 and the final awardees in September 2020.
Partners
growth-positive
Geisinger partners with EarlySign for AI algorithms to spot chronic disease
Geisinger is collaborating with Medial EarlySign to implement machine learning technology for the detection and prevention of chronic and high-cost diseases. The partnership will develop and deploy AI tools to identify patients at risk of various chronic conditions. The initial focus will be on using EarlySigns LGI-Flag technology to identify individuals at higher risk for lower gastrointestinal disorders. Geisingers advanced IT infrastructure and unique datasets will support the development of additional applications for acute and chronic diseases. The collaboration aims to lower costs, improve patient care, and advance population health and precision medicine goals.
Partners
growth-positive
EarlySign Unveils Commercial Availability of AI Diabetes Risk Predictors Algorithm
Medial EarlySign, an Israeli health AI company, has announced the commercial availability of its machine learning-based predictive diabetes risk solutions. The solutions, called Pre2D and Diabetes to CKD, help healthcare systems identify and engage patients at high risk for diabetes and chronic kidney disease. Pre2D identifies prediabetic patients at high risk of progressing to diabetes within twelve months, while Diabetes to CKD identifies type 2 diabetic patients at high risk of developing chronic kidney disease within three years. The solutions use advanced machine learning algorithms and routine blood tests to flag high-risk patients. The company aims to help healthcare systems initiate preventative measures and allocate resources to delay or prevent the onset of disease.
Customers
growth-positive
This Israeli startup aims to catch disease early with data not diagnostic tests
Medial EarlySign, an Israeli company, is using artificial intelligence to mine EHR data and detect colorectal cancer risk earlier. The company has launched two products to identify prediabetes patients and those at risk of developing chronic kidney disease. Medial EarlySigns AI tools will be featured at the annual meeting of the American Diabetes Association. The companys products have been validated through studies conducted by the University of Oxford and Kaiser Permanente Northwest. Medial EarlySign has already been used in Israel to identify high-risk patients for colorectal cancer, leading to the discovery of patients with malignancy and polyps. The company has raised $55 million in funding from investors including Horizons Ventures and aMoon.
Customers
growth-positive
SLUCare Selects Medial EarlySign's Artificial Intelligence Tool to Predict Patients at Risk for Lower GI Disorders
Medial EarlySigns machine learning-based solution, LGI Flag, will be implemented in SLUCare patient-care offices to help identify patients at greater risk of lower GI disorders. The implementation of this clinical risk identification tool is expected to improve care and long-term survival rates for patients. Medial EarlySign worked closely with SLUCare to deploy the algorithms effectively. The partnership between SLUCare and Medial EarlySign was facilitated by the BioSTL initiative GlobalSTL. The implementation of LGI Flag provides a competitive advantage for SLUCare and positions Medial EarlySign as a leader in health care innovation.
Partners
growth-positive
Medial EarlySign Expands U.S. Footprint With Appointment of Senior Executives
Medial EarlySign has announced the appointment of two senior executives in its Boston-area office to meet growing U.S. demand for its predictive analytics solutions. Patrick Wells, formerly with IBM Watson Health, has been appointed Chief Customer Success Officer, and Brandon Wilcher has been hired as Vice President of Sales in the North American Region. These new hires highlight Medial EarlySigns success in implementing its machine learning solutions within healthcare organizations and its commitment to ensuring organizations receive the highest quality insights to assist them in improving patients health. Medial EarlySigns machine-learning based technology is increasingly sought after in the U.S. and around the world.
Customers
growth-positive
Israeli smart software flags patients at risk for colon cancer
Israeli startup Medial EarlySign has developed machine learning-based software called ColonFlag, which analyzes blood test results to identify patients at high risk of colon cancer. The software is currently being used by Israels healthcare provider Maccabi. The artificial intelligence market for healthcare applications is expected to expand rapidly, with revenues reaching $6.7 billion by 2021. Medial EarlySign has raised $50 million in funding, including investments from the Li Ka Shing Foundation and aMoon Fund. The company is focused on the US market and has set up an office in Boston.
Customers
growth-positive
Medial EarlySign Appoints Chief Medical Officer
Medial EarlySign has appointed Jeremy Orr as Chief Medical Officer, emphasizing their commitment to providing precise insights to healthcare organizations using AI and machine learning algorithms. Dr. Orr brings extensive experience in patient care and healthcare IT, and his appointment is expected to contribute significantly to the companys suite of solutions and global implementations. Medial EarlySigns advanced AI-based algorithm platform helps healthcare organizations optimize care for individuals and prevent serious health conditions by leveraging routine blood test results and EHR data. The company is developing stratification models for various illnesses. Founded in 2009, Medial EarlySign is headquartered in Kfar Malal, Israel.
Management Changes
growth-positive
AI tool successfully identifies patients at high risk of CRC in real-world study
Medial EarlySigns machine learning-based cancer detecting solution has been successfully implemented in a study, detecting cases of colorectal cancer and advanced adenomas. The results show that the technology can provide a safety net in clinical practice. The implementation of machine learning algorithms to risk stratify populations at risk has been proven effective with the right setup of clinical leadership and technology.
Customers
growth-positive
Medial EarlySign's clinical validation trial shows promise for flagging colorectal cancer patients
A clinical validation study led by Israeli HMO Maccabi Health Services found that Medial EarlySigns AI tool, ColonFlag, flagged 8% of patients in a trial group who were later diagnosed with cancer or precancerous lesions. The study aimed to increase earlier detection of cancer among noncompliant patients through advanced screening with EHR data. Out of 79,671 patients, ColonFlag identified 688 individuals at risk for colorectal cancer. Physicians found colorectal cancers in 19 participants and advanced adenomas in 22 participants. Medial EarlySign is conducting clinical studies in 14 locations worldwide. The companys AI technology is also used for other medical conditions.
Customers
growth-positive
EarlySign Raises $30M in Series B Funding - FinSMEs
Medial EarlySign, a provider of machine-learning based solutions for patient management and non-communicable disease management, has raised $30 million in a Series B funding round. The funding, led by aMoon Fund, brings the companys total funding to $50 million. Medial EarlySign plans to use the funds to expand its suite of solutions and implement its technology globally. The companys AI-based algorithm platform leverages routine blood test results and EHR data to optimize care for individuals and prevent serious health conditions. Medial EarlySign has already been supported by peer-reviewed research and is working on developing stratification models for various illnesses. The funding round took place on June 3, 2018.
InvestmentExpand
growth-positive
Patient management co Medial EarlySign raises $30m
Israeli patient management startup Medial EarlySign has raised $30 million in a funding round led by Marius Nachts aMoon Fund. The company has developed machine-learning based technology to improve patient management and creates AI-powered software tools that provide health professionals risk predictors. The funding will be used to broaden the companys solutions and expand clinical research and global implementation of its technology. Medial EarlySign is currently conducting clinical data studies with over 20 million patients in 14 institutions.
Investment
growth-positive
Israeli AI Startup Can Predict Which Diabetes Patients Will Develop Kidney Disease
Israeli health startup Medial EarlySign has developed an artificial intelligence (AI) algorithm that can predict which diabetes patients will develop kidney dysfunction within a year. The algorithm analyses electronic health records, including lab test results, demographics, medication and diagnostic codes. The companys database of 15 million patients was used to identify 45% of patients who would progress to significant kidney damage within a year, prior to becoming symptomatic. This represents 25% more patients than would have been identified by commonly used clinical tools and judgment.
CustomersExpand
growth-positive
Medial EarlySign Named a Gartner Cool Vendor in AI for Healthcare
Medial EarlySign has been selected by Gartner as a Cool Vendor for Artificial Intelligence (AI) in Healthcare. The company develops machine learning-based algorithms to identify individuals at risk of various health conditions by analyzing routine EHR data and clinical data. Medial EarlySigns first commercialized tool, ColonFlag, has been successfully implemented by integrated delivery networks. The recognition from Gartner highlights the value of Medial EarlySigns predictive technology and its potential to help healthcare providers improve outcomes and reduce costs.
Partners
N/A
Cool Vendors in AI for Healthcare, 2017
The article discusses the opportunities in healthcare through the application of AI and advanced analytic techniques. It highlights cool vendors in the industry and emphasizes the rapid innovation and transformation in digital medicine. CIOs can use this research to stay ahead of the trends.
growth-positive
Medial EarlySign Enables Leading Israeli HMO to Identify Pre-Symptomatic Patients at High Risk for Cancer
Medial EarlySign has announced the first-year results of its implementation with Maccabi Healthcare Services (MHS) for its tool, ColonFlag, which identifies individuals at high risk of colorectal cancer. Maccabi is using ColonFlag to analyze its members electronic medical records and identify the top 1% at highest risk of undiagnosed CRC. Over the first twelve months, ColonFlag evaluated almost 80,000 individuals, with 690 flagged as high risk. Of the 690 patients identified, 220 colonoscopies were performed, resulting in 20 cases of cancer being detected. Medial EarlySigns technology has the potential to accurately indicate subpopulations at risk of various health conditions. ColonFlag is not yet cleared by the FDA for commercial use in the USA.
Customers
http://www.israelhayom.com/site/newsletter_article.php?id=25455
Medial EarlySign Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 12 |
| Team members | 8 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
Medial EarlySign Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514205269 |
| Crunchbase | medial-earlysign |
| Phone | +972722408777 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-24T00:00:00.000Z |
| Created | 2014-12-30T00:00:00.000Z |